Sab biotherapeutics to present at sidoti virtual investor conference, may 10-11

Sioux falls, s.d., may 03, 2023 (globe newswire) -- sab biotherapeutics (nasdaq: sabs), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human, multi-epitope binding immunoglobulin igg1 (polyclonal) antibodies without the need for human donors, is pleased to announce that eddie sullivan, phd, co-founder, president & ceo of sab biotherapeutics, will be presenting and hosting one-on-one meetings with investors at the upcoming sidoti virtual investor conference on may 10 at 11:30am et. the presentation can be accessed live at: https://sidoti.zoom.us/webinar/register/wn_hky73f7pst6rja3todnaaq.
SABS Ratings Summary
SABS Quant Ranking